1. O-132 Sustained efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT 52-week data. (6th August 2021) Authors: As-Sanie, S; Giudice, L; Abrao, M S; Wilk, K; Mehedintu, C; Becker, C; Arjona Ferreira, J C; Wagman, R B; Wang, F; Warsi, Q A; Neil, J Journal: Human reproduction Issue: Volume 36:Supplement 1(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. O-136 Once-daily relugolix combination therapy results in sustained reduction in symptoms and improved quality of life in women with uterine fibroids treated over 52 weeks. (6th August 2021) Authors: Lukes, A; Venturella, R; Al-Hendy, A; Nyirady, T; Decleer, W; Petraglia, F; Li, Y; Wagman, R B; Hunsche, E; Stewart, E A Journal: Human reproduction Issue: Volume 36:Supplement 1(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗